Novo Nordisk Q4 Earnings: Outperformance Suggests Stock Price Comeback Starts Today
Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...
Novo Nordisk posts net profit beat as Wegovy sales jump 107% in fourth quarter
Danish pharmaceutical behemoth Novo Nordisk reported better-than-expected net profit in the fourth quarter, amid soaring ...
Novo Nordisk next-gen shot shows 22% weight loss in early results
One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...
Yahoo Finance29d
Metsera announces positive results in newest Phase IIa GLP-1RA
New York obesity healthcare firm, Metsera, has unveiled positive topline results from its Phase IIa trial of its glucagon-like peptide-1 receptor ... weight loss drug, CagriSema, fell short ...
FoodBusinessNews22d
Reduced spending by GLP-1 users hits frozen category hardest
GLP-1, or glucagon-like peptide-1 drugs, can help people lose weight by reducing their appetite and slowing digestion. The most prescribed GLP-1 drugs include Ozempic, Wegovy, Mounjaro, CagriSema ...
Novo Nordisk: Next-Generation GLP-1/Amylin Drug Sees Leading Weight Loss in Small Trial
Novo Nordisk’s NVO amycretin, which targets GLP-1 and amylin in one molecule, generated 24% placebo-adjusted weight loss in a ...
Novo Nordisk shares surge on results of new obesity drug trial
Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...
rheumatologyadvisor26d
REDEFINE 1 Trial: Superior Weight Loss Seen With CagriSema
CagriSema is a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), that works by decreasing hunger and ...